In KEYNOTE-045 (NCT02256436) pembrolizumab improved overall survival over investigator’s choice of paclitaxel, docetaxel, or vinflunine as second-line therapy for advanced bladder cancer after platinum-based chemotherapy (HR 0.73; P = 0.0022). In the initial trial there were fewer treatment-related adverse events. were reported with pembro. The purpose of this abstract was to present the results from a prespecified HRQoL analysis of KEYNOTE-045. Use of the EORTC QLQ-C30 HRQoL instrument had good compliance (88%). Results demonstrated that pembrolizumab was associated with substantially better HRQOL than investigator chosen second line chemotherapy. Now Pembrolizumab has high level evidence stating it has improved survival, fewer adverse events and improved quality of life making it a standard as second line therapy after cisplatinum based chemotherapy.
Clinical trial information: NCT02256436
Author: David J. Vaughn
Written By: Michael J Metcalfe, MD, Fellow of Urologic Oncology Urology, MD Anderson Cancer Center, Houston TX
Ashish M. Kamat, MD, MBBS, FACS, President, International Bladder Cancer Network Chair, Society of Immunotherapy for Cancer (SITC), BCTF, Director of Urologic Oncology Fellowship, Professor of Urology, Attending Surgeon, Division of Surgery, The University of Texas, MD Anderson Cancer Center, Houston TX
at the 2017 Genitourinary Cancers Symposium - February 16 - 18, 2017 – Orlando, Florida USA